LPTX

LPTX

Last Updated:

Q3 '20

Leap Therapeutics

Therapies targeting cancer cell signaling and T cells offer new options for patients with cancer. We are committed to making a difference in the lives of cancer patients.

Cash

$58M

Burn Rate (Qtr)

$7.1M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

DKN-01 +/- Paclitaxel

Carcinosarcoma (Gynecologic Cancer)

Phase 3 Initiation

DKN-01 + tislelizumab +/- CAPOX

Gastroesophageal Cancer / Gastroesophageal Junction Cancer

Phase 2 Readout

H2 '21

DKN-01

esophagogastric cancer (EC)

Phase 1/2 Data Presented at SITC 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon